(Finance) – The Board of Directors of Diasorin, today examined and approved the 2024-2027 Industrial Plan which “reaffirms the Company’s focus on the implementation of the strategic projects” presented during the 2021 Investor Day.
Following theacquisition of LuminexDiasorin has a more diversified portfolio of products and technologies, capable of capturing different growth trajectories, as well as a significantly greater critical mass and presence in the United States, the largest IVD market in the world and the most rewarding from the point of view of view of innovation.
The acquisition of Luminex – explains the company in a note – has allowed Diasorin to access multiplexing technology and strengthen its presence in molecular diagnostics, while allowing entry into the Life Science sector with a unique technology, appreciated by main players in this market.
All this has increased the Company’s resilience and its ability to better face the new challenges posed by recent macroeconomic and geopolitical developments, continuing to create value for its shareholders.
Carlo Rosa, CEO of Diasorincommented: “The 2024-2027 Industrial Plan approved today by the Board of Directors confirms and expands the strategic trajectories that will guide the development of Diasorin in the coming years. The completion of existing strategic projects and the launch of new initiatives will support our growth over the plan period. We are very satisfied with the positioning of Diasorin following the pandemic and the integration with Luminex and we are confident that we will continue to create value for our shareholders, as we have always done in the past”.
There guidance 2024-2027 at constant exchange rates, he predicts revenues in 2024: increasing by 5%-7% ex-Covid; Covid revenues equal to approximately 30 million. Over the 2024-2027 plan, revenues are expected to grow from High Single Digit to Low Double Digit (CAGR),
L’EBITDA Adjusted Margin it is expected next year at 32%-33%. At the end of the plan (2027) at 36%-37%.